Get the Stockscreener App
10.67
2.69%
0.28
After Hours:
10.67
Envveno Medical Corp stock is traded at $10.67, with a volume of 2,711.
It is up +2.69% in the last 24 hours and down -1.57% over the past month.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$10.39
Open:
$9.9
24h Volume:
2,711
Relative Volume:
0.18
Market Cap:
$7.12M
Revenue:
-
Net Income/Loss:
$-18.82M
P/E Ratio:
-0.3421
EPS:
-31.1883
Net Cash Flow:
$-14.79M
1W Performance:
-3.26%
1M Performance:
-1.57%
6M Performance:
+4.20%
1Y Performance:
-93.85%
1-Day Range:
$9.85
$10.67
1-Week Range:
$9.85
$11.19
52-Week Range:
$8.67
$184.45
Envveno Medical Corp Stock (NVNO) Company Profile
Name
Envveno Medical Corp
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
10.67 | 6.94M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp Stock (NVNO) Latest News
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
enVVeno Medical Corp (NVNO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineProfit Guidance Range - dars.gov.et
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineEarnings Manipulation Risk - dars.gov.et
EnVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor What This Means Segment - marketscreener.com
enVVeno Medical Updates Investors With New Presentation - The Globe and Mail
enVVeno Medical highlights newly issued U.S. patent - TipRanks
enVVeno Medical (NVNO) Secures U.S. Patent and Advances FDA Tria - GuruFocus
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment - ACCESS Newswire
enVVeno's non-surgical valve trial gets first-ever FDA IDE approval - Stock Titan
enVVeno Medical (NASDAQ: NVNO) releases updated investor presentation - Stock Titan
enVVeno Medical Corporation (NVNO) Q3 2025 Earnings: Narrower-Than-Expected Loss Bolsters Cash Runway FocusSubscription Growth Report - dars.gov.et
Price to earnings forward of enVVeno Medical Corporation – BOATS:NVNO - TradingView
NVNO Forecast — Price Target — Prediction for 2027 - TradingView
A42085 Forecast — Price Target — Prediction for 2027 - TradingView
enVVeno Medical receives U.S. patent for venous valve system By Investing.com - Investing.com Nigeria
enVVeno Medical receives U.S. patent for venous valve system - Investing.com
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial - ACCESS Newswire
enVVeno patent covers key enVVe valve parts before pivotal FDA trial - Stock Titan
enVVeno Medical (NVNO) Gains 2.6% as Shares Test Key Resistance Near $11.67Ascending Triangle - dars.gov.et
NVNO Q3 2025 Earnings: Narrowing Losses Underpin Optimism as Clinical Progress ContinuesMid-Term Outlook - dars.gov.et
NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineTech Earnings Analysis - dars.gov.et
Enterprise value to revenue forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Price to sales forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Price to sales forward of enVVeno Medical Corporation – FWB:5HJ0 - TradingView
Price to book forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Price to earnings forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Enterprise value to EBITDA forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Price to book forward of enVVeno Medical Corporation – FWB:5HJ0 - TradingView
enVVeno Medical Corporation Actuals & Estimates (FWB:5HJ0) - TradingView
enVVeno Medical Corporation Actuals & Estimates (NASDAQ:NVNO) - TradingView
enVVeno Medical Corporation Actuals & Estimates (BOATS:NVNO) - TradingView
enVVeno Medical Corp (NVNO) Institutional Confidence - TradingKey
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series - ACCESS Newswire
FDA-cleared venous valve study takes center stage at enVVeno webinar - Stock Titan
enVVeno Medical (NVNO) Dips 1.96%, Testing Support at $9.5Strong Buy Stocks - dars.gov.et
enVVeno Medical Corp (NVNO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
enVVeno Medical Corp (NVNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enVVeno Medical Corp (NVNO) Valuation: PE, PB & Fair Value Analysis - TradingKey
enVVeno Medical Corp (NVNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
enVVeno Medical (NVNO) Retreats 1.96% as Stock Navigates Key Support at $9.50Value Stock Ideas - newsline.com
Insider Selling: Francis Duhay Sells Shares of enVVeno Medical C - GuruFocus
Envveno Medical Corp Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):